Test Price
2,800 AED✅ Home Collection Available
MECP2 Gene Analysis (X-Linked Mental Retardation Type 13) NGS Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation from our DHA-licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
The MECP2 Gene NGS test delivers comprehensive pathogenic variant screening across the entire MECP2 coding region, splice sites, and CNV analysis. This test is the cornerstone diagnostic tool for Rett syndrome (F84.2) and X-linked intellectual disability type 13 (F72), enabling early intervention, targeted therapies, and informed genetic counseling under DHA regulatory oversight.
Test Overview & Methodology
This advanced sequencing test utilizes Next-Generation Sequencing to detect single-nucleotide variants, small insertions/deletions, and copy-number variations across the MECP2 gene. Full gene coverage ensures detection of mutations in coding exons, intronic boundaries, and regulatory regions essential for accurate diagnosis of Rett syndrome and X-linked intellectual disability phenotypes. Results are correlated with clinical presentation and family pedigree analysis by our genetics team.
| Feature | Our NGS MECP2 Test | Standard Targeted Sequencing |
|---|---|---|
| Methodology | Next-Generation Sequencing (Full gene coverage) | Sanger Sequencing (Exon-limited) |
| Variant Detection | All coding exons + splicing sites, CNV analysis | Point mutations only, limited CNV |
| Turnaround Time | 3 – 4 Weeks | 6 – 8 Weeks |
| Clinical Sensitivity | >99.9% | ~95% |
| Price (AED) | 2,800 | 3,500+ |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), DHA Licensed | Varies |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I recognise the profound impact a genetic diagnosis can have on a family navigating a child’s developmental challenges. The MECP2 gene analysis provides definitive molecular answers, yet the interpretation must always be integrated with a detailed family history, neurological assessment, and developmental trajectory. A collaborative approach between genetics, neurology, and paediatrics ensures the most accurate prognostic guidance and therapeutic planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Pre-Test Genetic Counseling Advisory
A mandatory pre-test genetic counseling session is required for all patients prior to sample collection. This session covers the implications of potential results, recurrence risks, and the scope of conditions detected. A detailed three-generation family pedigree is documented to assess inheritance patterns and guide variant interpretation. Consent is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Safety Exclusion Criteria & Emergency Red Flags
- Patients currently receiving urgent oncological or life-sustaining treatment; defer genetic testing until clinical stabilisation is confirmed by the treating physician.
- Children under 2 years require explicit parental or legal guardian consent plus mandatory pre-test genetic counseling as stipulated under UAE health regulations.
- Emergency red flags: Acute neurological deterioration, new-onset seizures with loss of consciousness, signs of raised intracranial pressure (severe headache, vomiting, altered consciousness) — seek immediate emergency medical attention at the nearest hospital.
Patient FAQ & Clinical Guidance
1. What is the MECP2 gene and why is this test important?
Quick Guide: MECP2 gene mutations cause Rett syndrome and X-linked intellectual disability, making this test critical for early behavioural and neurological intervention.
The MECP2 gene provides instructions for methyl-CpG-binding protein 2, essential for normal brain development and synaptic function. Pathogenic variants lead to severe neurodevelopmental disorders primarily affecting girls (Rett syndrome) and causing moderate-to-profound intellectual disability in boys. Early diagnosis through this comprehensive NGS test enables timely supportive therapies, access to gene-specific clinical trials, and precise genetic counselling for family planning.
2. How is the sample collected and what are the requirements?
Quick Guide: A simple blood draw is collected via VIP Mobile Phlebotomy at your home between 8 AM and 11 PM, with no fasting required but mandatory pre-test genetic counseling.
A certified mobile phlebotomist arrives at your doorstep using a temperature-controlled cold-chain specimen kit. Acceptable samples include whole blood (EDTA tube), extracted DNA, or a single drop of blood on an FTA card. Pre-test preparation mandates a genetic counseling session to draw a detailed family pedigree of MECP2-related conditions. No fasting is needed, but a completed clinical history form is compulsory. Sample collection follows ISO 9001:2015 accredited protocols under DHA supervision.
3. What do the results mean for my child's future treatment?
Quick Guide: Positive results guide targeted therapies and clinical trials, while negative results provide reassurance but may require further evaluation if clinical suspicion persists.
A positive (pathogenic) result confirms the specific MECP2 variant responsible for the condition, allowing the medical team to tailor interventions, predict disease progression, and access gene-specific therapies or ongoing clinical trials. A negative result significantly reduces the likelihood of classic MECP2-related disorders, but further testing such as whole exome sequencing may be recommended if clinical suspicion remains high. All results are interpreted alongside the patient's neurological profile by our DHA-licensed Consultant Medical Geneticist, and a post-test telephonic guidance session is included at no additional cost.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of patient data protection and clinical governance. All genetic data generated from the MECP2 Gene Analysis test is processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient samples are de-identified and secured within encrypted laboratory information systems. Results are released only to the ordering physician or the patient with verified consent, ensuring complete confidentiality and ethical handling of genetic information.
Clinical & Logistical Metadata
| Test Name | MECP2 Gene Analysis (X-Linked Mental Retardation Type 13) NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coverage including coding exons, splice sites, and CNV analysis |
| ICD-10-CM Code | F84.2, F72 |
| LOINC Code | 21679-7 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians